Tagged with Pricing

IMS IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014, what trends are shaping the industry as well as the moderate, yet positive outlook for 2015. How would you assess…

MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…

Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…

GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…

Recordati Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the group) to the global organization, and current initiative to increase investment and develop a new manufacturing facility in the country.…

Chiesi Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government to clarify the incentives that have been discussed? The healthcare system in Turkey has undergone the largest transition in its…

Biocodex Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted you to Biocodex Turkey? What are your impressions of the business so far? Biocodex made the right decision in starting…

Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards.  In 2012, you had made it a goal to develop the Turkish affiliate into a regional…

Ferring The general manager of a speciality biopharma business challenges lawmakers to regard health spending not as a cost but as an investment and reveals how women’s healthcare and fertility treatment can become showcase examples in making Romanian healthcare sustainable. Back in 2011, when we asked you about Ferring’s priorities in…

Pfizer One of the new cohort of country managers speaks out about Romania’s blossoming potential as a manufacturing hub and explains in detail how his firm is diverting product lines form elsewhere in Europe and relocating them in Cluj so as to exploit what he sees as a real competitive advantage.…

market access Many of the multinational companies with a long-standing presence in Latin America used to have factories in Peru – since the 1990s all of these companies have closed their facilities in the country as part of a consolidation process to other larger countries in the region like Mexico, Brazil or…

Janssen Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement. Based on current discussions, what is your expectation for how pricing reforms will transpire when they begin?  The government is…